Halozyme Therapeutics (HALO) stock slips as Morgan Stanley downgrades the company, citing valuation concerns following its recent Q3 2026 results. Read more here.
Halozyme Therapeutics Inc (HALO) posted 39% revenue growth with record royalties, lifted its full-year 2026 outlook, and scored a Dutch patent victory against Merck even as US litigation drags on.
Halozyme's tech allow IV drugs to be given instead with shots.
Detailed price information for Apa Corp (APA-Q) from The Globe and Mail including charting and trades.
Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron stand out for strong share gains and rising earnings estimates under a relative price strength strategy.
Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 5 years by 12.8% on an annualized basis producing an average annual return of 24.48%. Currently, Halozyme Therapeutics has a market
Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.
Argenx (ARGX) stock drops as the firm ends a late-stage trial for an injectable version of its blockbuster therapy, Vyvgart targeting Sjögren's disease. Read more here.
This is the newest page. Registered accounts read further back.